Pharmx Technologies Limited · ASX:PHX
Pharmx Technologies — Investor Presentation (February 2025)
27 slides from Pharmx Technologies's investor presentation, Feb 19, 2025
Slide 1: Investor Presentation
Investor Presentation PHARMX TECHNOLOGIES LIMITED (ASX:PHX) Tom Culver, CEO Jon Newbery, COO 19 February 2025
Slide 2: Notice & Disclaimer
Notice & Disclaimer This presentation has been prepared by Pharmx Technologies Limited (Pharmx or the Although the Company believes that the expectations reflected in the forward-looking Company or PHX). It should not be considered as an offer or invitation to subscribe for, statements included in t
Slide 3: Presenters
Presenters Chief Executive Officer Non-Exec Director / COO Tom Culver Jon Newbery
Slide 4: 1H Update Company Overview
1H Update Company Overview • Year on year performance remains strong with uplifts in revenue and activity across all key metrics. This is supported by continued positive ASX Code PHX trends in Beauty, Vapes and Medicinal cannabis. • Investment in people and technology has led to increased operating
Slide 5: Pharmx Overview
PHARMX OVERVIEW ANZ's largest pharmacy network ¢ Deliver critical infrastructure that supports the entire ANZ pharmacy industry. ¢ The leading independent, whole-of-market provider making a difference to healthcare by re imagining how the industry connects. 80k SKUs from hundreds of leading supplier
Slide 6: Dominant Position
PHARMX OVERVIEW Dominant Position STRONG MARKET POSITIONING GROWTH OPPORTUNITY 99% of pharmacies see the Pharmx offering to 85% of the pharmacy market has confirmed strong be high quality, with 76% rating it as either 'very appeal and viability of Pharmx’s product good' or 'excellent'. development p
Slide 7: Growth accelerated by favorable market conditions
PHARMX OVERVIEW G RO W IN G PO PU L A TIO N & S H I F TING D E MOG RAPH ICS 33.1m +100% 81% Growth A ustralia’ s population is Those aged over 85 81. 4% of people have forecast to grow to 33. 1m y ears will double by at least one long-term by 20 41. 2041. health condition. ABS 2022 ABS 2022 Preventi
Slide 8: Competitive Advantages
PHARMX OVERVIEW Competitive Advantages The industry’s first Direct access to the Whole-of-market technology choice biggest network 18 years of making a difference. Connecting 99% of ANZ Developed with modern cloud- 93% brand awareness, with 80% pharmacies, hundreds of leading based architecture we d
Slide 9: Operating in a large market
PHARMX OVERVIEW Operating in a large market GATEWAY MARKETPLACE ANALYTICS TAM TAM TAM $720m ARR $240m ARR $725m ARR SAM SAM SAM $216m ARR $141m ARR $205m ARR SOM SOM SOM $18m ARR $21m ARR $12m ARR CAGR to 2030: 7.27% Pharmacy Market CAGR to 2027: 17.5% B2B Services CAGR to 2030: 17.7% Global Data Se
Slide 10: Growth Strategy
PHARMX OVERVIEW Growth ANALYTICS SUPPLIER CAPABILITY GROWTH Increased market share Targeted increase in direct boosts purchasing activity, suppliers across the Pharmx Strategy generating richer data that network and through vertical further enhances our integration as the driver of solutions, which
Slide 11: H1 Highlights
H1 HIGHLIGHTS Rebranding Analytics Capability H1 • Pharmx’s refreshed brand identity reinforces its commitment to delivering confidence and convenience • • Data platform and analytics capability in market Pharmx Analytics helps suppliers and pharmacies Highlights make better decisions, reduce costs,
Slide 12: Platform metrics
H1 HIGHLIGHTS S U PPL I ER & A C C O U NT G R O W TH Platform +10% Increase in total Suppliers +4% Increase in A ccount connections Gateway Y TD +6% Increase in account growth metrics Pharmx YTD Marketplace YTD V O L U M E G R O W TH Platform performance remains strong with uplifts in revenue and ac
Slide 13: Financial Update
H1FINANCIALS Financial Update H1 FY25 H1 FY25 H1 FY25 17% 12% 10x Growing Revenues Gateway Revenues Marketplace Revenues $3.77m, ~17% above H1 FY24 Gateway revenues increase 10-fold increase in revenues compared to H1 FY24 compared to H1 FY24 H1 FY25 H1 FY25 December 2024 ~$1.04m ~2.7m $4.5m Steady
Slide 14: Profit & Loss H1 FY25
H1FINANCIALS Profit & Loss H1 FY25 Strong revenue growth compared to prior comparative period $’000 H1 H1 Change Var % • Revenue growth of 17% driven by increased activity FY25 FY24 across both Gateway and Marketplace platforms, with Revenue 3,773 3,235 538 17% new suppliers and growth in connection
Slide 15: Cashflow
H1FINANCIALS Cashflow • Positive underlying operating cashflow delivered after adjusting for the impact of the Pharmx legal Positive operating cashflow case. Includes increased investment in people, $’000 H1 FY25 H1 FY24 Change Var % marketing and IT infrastructure Receipts from customers - continui
Slide 16: Maximising Brand Equity
H1 INITIATIVES Maximising Brand Equity • Reinforcing market leadership: The refreshed brand This rebrand ensures we continue to evolve as the communicates our commitment to delivering market leader while delivering both customer and confidence, convenience, and trust values that resonate shareholder
Slide 17: Pharmx Analytics
H1 INITIATIVES Pharmx Analytics Delivering data and analytics through AI. Reliable data, secure platform Deepest and most broad dataset in ANZ Modern AI support platform, built to scale Best-in-class security and privacy Drives growth by customer value Improves our customer’s business Increases supp
Slide 18: Single Platform
H2 INITIATIVES NEW Single Platform Fully integrated, consolidate Pharmx platform that significantly improves customer experience and creates technology, growth and resource efficiencies to scale Pharmx into a larger market opportunity. Creates more value for our customers; Suppliers, Pharmacies and
Slide 19: Enhanced Supplier Portal
H2 INITIATIVES NEW Enhanced Supplier Portal The fastest and most efficient way for suppliers to connect and do business with 99% of the ANZ pharmacy industry. • The new supplier portal onboarding from 12 weeks to as little as one day. • Upgraded tools to help suppliers manage and grow their business
Slide 20: Investment Highlights
Investment Highlights • Year on year performance remains strong with uplifts in revenue and in activity across all key metrics. • Continue to be the dominant independent ordering network in the region, cemented with NZ expansion through our Toniq partnership. • Strong strategic growth agenda support
Slide 21: Thank you
Thank you Suite 11.02, Level 11,17 Castlereagh Street, Sydney 2000 investor.relations@Pharmx.com.au
Slide 22: Appendix
Appendix 22
Slide 23: Corporate Overview
Corporate Overview Pharmx Technologies Limited as at 17 February 2025 Capital Structure Share Price $0.083 Shares on issue (m) 598.5 Market Capitalisation $49.68m Options / Perf Rights (m) 12.0 Enterprise Value (Cash 31/12/24) $45.2m Diluted Issued Capital (m) 610.5 Share Price Performance
Slide 24: Profit & Loss
$’000 H1 FY25 H1 FY24 Var $ Var % Revenue 3,773 3,235 538 17% Cost of sales (669) (610) (59) 10% Marketing (166) (65) (101) 156% Employee benefits (1,443) (1,022) (421) 41% Share-based payments (24) (39) 15 -38% Technology, communication and cloud costs (258) (201) (57) 28% Legal (25) (4) (21) 537%
Slide 25: Cash Flow
$’000 H1 FY25 H1 FY24 Cash flows from operating activities Receipts from customers 4,192 4,683 Payments to suppliers and employees (14,079) (4,503) Interest and other revenue received 117 93 Research and development incentive received, net of income tax paid 862 1,663 Net cash from operating activit
Slide 26: Balance Sheet
$’000 31 Dec 2024 30 Jun 2024 Current assets Cash and cash equivalents 4,482 13,136 Trade and other receivables 912 2,271 Income tax receivable 35 883 Other assets 239 79 Total 5,668 16,369 Non-current assets Property, plant and equipment 30 17 Right of use assets 172 226 Intangibles 11,894 12,930 D
Slide 27: Share Registry
Position Holder Name Holding % IC 1 LUJETA PTY LTD <MARGARET A/C> 98,480,946 16.45% 2 BNP PARIBAS NOMINEES PTY LTD <IB AU NOMS RETAILCLIENT> 70,021,175 11.70% 3 ARROTEX INVESTMENTS HOLDING 1 PTY LTD 60,000,000 10.02% 4 MERSAULT PTY LTD <ENGLAND S/F A/C> 26,766,667 4.47% 5 HSBC CUSTODY NOMINEES (AUST
Pharmx Technologies — Investor Presentation (February 2025) on 6ix